L'Oreal Evaluates Offloading Legal Liabilities Through Corporate Spin-off

L'Oreal is evaluating a strategy to isolate and divest U.S. legal liabilities linked to talc and chemical ingredients. The company intends to shield its core operations from mounting litigation. The cosmetics firm has engaged outside counsel and financial advisers to explore structural options for managing these claims, which have increased throughout 2026.

To manage this process, L'Oreal has retained restructuring counsel Weil Gotshal & Manges and investment bank Ducera Partners. This move follows a trend among multinational corporations to separate mass-tort exposure from their primary business entities.

Scaling Legal Exposure

The company's legal challenges expanded during the first half of the year. As of June 30, 2026, L'Oreal reported 760 pending U.S. proceedings related to alleged asbestos particles in talc-containing products, up from 620 at the end of 2025.

In addition to talc litigation, the firm faces scrutiny regarding its hair relaxer portfolio. In September 2026, the state of Arizona filed a lawsuit alleging that these products could cause cancer, adding regulatory and legal pressure to the company's U.S. operations.

The Divestiture Mechanism

Advisers are evaluating a model similar to the one used by Honeywell in 2025, when the industrial conglomerate sold asbestos-related liabilities to a platform known as Delticus. This mechanism allows a company to transfer tort exposure to a separate, bankruptcy-remote entity. This process removes the litigation from the parent company's balance sheet and operational oversight.

This strategy differs from traditional Chapter 11 bankruptcy, which often involves broader restructuring. By utilizing a targeted divestiture, companies attempt to contain the financial impact of litigation while maintaining the stability of their core business segments.

What Is at Stake for Shareholders

The potential separation of these liabilities is a tactical effort by L'Oreal to limit the long-term uncertainty surrounding its U.S. product portfolio. For the cosmetics manufacturer, successfully isolating these claims is intended to clarify the company's valuation by decoupling its operating performance from the costs associated with mass-tort settlements and legal defense fees.